(Q37765619)

22 August 2017

1 reference

title

The quest for new anticoagulants: from clinical development to clinical practice (English)

1 reference

22 August 2017

1 reference

1 reference

2

Gregory Y H Lip

1 reference

22 August 2017

4

Eduard Shantsila

1 reference

22 August 2017

3

Deirdre A Lane

1 reference

22 August 2017

1

Stavros Apostolakis

1 reference

22 August 2017

publication date

14 June 2010

1 reference

Cardiovascular Therapeutics

22 August 2017

published in

1 reference

22 August 2017

volume

29

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

e12-22

1 reference

Remodeling the blood coagulation cascade

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

The blood coagulation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

21 January 2018

The discovery of heparin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

The story of the discovery of heparin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Novel oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Fondaparinux: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

New anticoagulants for treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Idraparinux versus standard therapy for venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

New anticoagulants: focus on venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Investigational treatments of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00160.X

10.1111/J.1755-5922.2010.00160.X

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference